Literature DB >> 1794353

Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide.

H G Wieser1.   

Abstract

The concentration of valproate was measured in plasma, CSF and brain tissue of patients who underwent resective surgical treatment because of severe temporal lobe epilepsy after pretreatment with either a sustained release formulation of valproate (Depakine Chrono; 5 patients), the conventional formulation of valproate (Depakine; 6 patients) or valpromide (Depamide; 2 patients). With a mean serum value for all 13 patients of 32.3 micrograms/g valproate, the mean brain/serum ratio was 15.1% (SD 6.1%). The valproate concentration of the hippocampus was significantly higher than that of the amygdala and patients who had the sustained release formulation had significantly higher valproate concentration in the CSF and in the hippocampal formation than those patients who had the conventional valproate. Since a few patients had tumors, whereas others had varying degrees of gliosis, it cannot be ruled out that these differences are the result of different histopathological conditions with related differences in blood-brain barrier functions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794353     DOI: 10.1016/0920-1211(91)90028-e

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

2.  Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics.

Authors:  José L Herranz; Rosa Arteaga; Javier Adín; Juan A Armijo
Journal:  Eur J Clin Pharmacol       Date:  2006-08-02       Impact factor: 2.953

3.  Neuropathological findings in 224 patients with temporal lobe epilepsy.

Authors:  K H Plate; H G Wieser; M G Yasargil; O D Wiestler
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.

Authors:  Clare L Killick-Cole; William G B Singleton; Alison S Bienemann; Daniel J Asby; Marcella J Wyatt; Lisa J Boulter; Neil U Barua; Steven S Gill
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.